<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>NVO &mdash; Novo Nordisk: regulatory | Trader Notes</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Lato', -apple-system, sans-serif; background: #FFF1E5; color: #1a1a2e; line-height: 1.6; }
        .container { max-width: 760px; margin: 0 auto; padding: 1.5rem; }
        a { color: #0d7680; }
    </style>
    <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@700&family=Lato:wght@300;400;700&display=swap" rel="stylesheet">
</head>
<body>
<div class="container">
    <div style="margin-bottom:1rem">
        <a href="../" style="font-size:0.8rem;color:#6b7280;text-decoration:none">&larr; Back to Trading Sheet</a>
    </div>

    <div style="display:flex;align-items:center;gap:12px;margin-bottom:0.5rem;flex-wrap:wrap">
        <span style="font-family:'Playfair Display',serif;font-size:1.8rem;font-weight:700">NVO</span>
        <span style="font-size:0.8rem;padding:4px 12px;border-radius:12px;color:#7c3aed;background:#f3e8ff;font-weight:700">KILLED</span>
        <span style="font-size:0.85rem;color:#6b7280">SHORT 44% &middot; Band D</span>
    </div>
    <div style="font-size:1rem;color:#4b5563;margin-bottom:0.5rem">Novo Nordisk: regulatory</div>

    <div style="display:flex;gap:1.5rem;flex-wrap:wrap;margin:1rem 0"><div><div style="font-size:0.7rem;color:#6b7280;text-transform:uppercase">DD Price</div><div style="font-weight:700;font-size:1.1rem">$49.23</div></div><div><div style="font-size:0.7rem;color:#6b7280;text-transform:uppercase">Current</div><div style="font-weight:700;font-size:1.1rem">$49.23</div></div><div><div style="font-size:0.7rem;color:#7c3aed;text-transform:uppercase">Report P&amp;L</div><div style="font-weight:700;font-size:1.1rem;color:#7c3aed">+0.0%</div></div></div>
    <div style="margin:0.5rem 0"><span style="display:inline-block;padding:3px 10px;border-radius:12px;font-size:0.75rem;font-weight:700;color:#991b1b;background:#fef2f2">INVALIDATED</span> <span style="display:inline-block;padding:3px 10px;border-radius:12px;font-size:0.75rem;font-weight:700;color:#991b1b;background:#fef2f2">&#128680; mainstream (15)</span></div>
    <div style="margin:1rem 0">
                <div style="font-size:0.75rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:4px">Conviction</div>
                <div style="display:flex;align-items:center;gap:10px">
                    <div style="flex:1;max-width:200px;height:8px;background:#e5e7eb;border-radius:4px;overflow:hidden">
                        <div style="width:20%;height:100%;background:#cc0000;border-radius:4px"></div>
                    </div>
                    <span style="color:#cc0000;font-weight:700;font-size:1.1rem">2/10</span>
                </div>
            </div>
    <div style="background:#f9fafb;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;color:#374151;border-left:3px solid #7c3aed"><strong>Status:</strong> KILL (watching): The thesis around Novo Nordisk appears to have lost its edge as seen by the substantial coverage from major outlets, indicating that the market sentiment may have already absorbed and reacted to the r</div>
    <div style="margin:1rem 0;padding:1rem;background:#fefce8;border-radius:6px;border-left:3px solid #eab308"><div style="font-size:0.75rem;color:#92400e;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:6px">Original Report Thesis</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Mechanism:</strong> The system’s direction is SHORT because the thesis is framed as regulatory and legal pressure around Novo Nordisk - a mechanism that can hit growth narratives in GLP-1 via constraints, litigation drag, or credibility risk, even before it hits numbers. This is not a “maybe” story in the ecosystem sense: it is already a widely covered storyline. The edge question is whether there is still incrementa</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Tripwire:</strong> INVESTIGATE reflects timing reality: Tier-1 outlets are already engaged, so the first repricing impulse is likely past. In a Mixed 62 tape with crosswind 72, shorting a high-attention name without a fresh primary artefact is structurally risky because sentiment can reverse on a single reassuring hea</div><div style="font-size:0.85rem;color:#374151;margin-bottom:6px"><strong>Evidence:</strong> Upstream lists multiple Tier-1 domains (Reuters/WSJ/NYT/FT, etc.) as engaged, which is the defining evidence for edge decay in this signal. This cycle does not include a specific Novo-linked URL in hydrated evidence for this item, so the evidence anchor is the domain set described upstream: reuters.com and fda.gov.</div><div style="font-size:0.85rem;color:#b45309"><strong>Risks:</strong> risky because sentiment can reverse on a single reassuring headline.</div></div>
    <div style="background:#f0fdf4;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;border-left:3px solid #22c55e"><strong>&#128269; Watching For:</strong> I will be looking for specific regulatory updates or developments that could provide new insight or shift the sentiment. Essentially, any new information that would refresh the narrative around Novo Nordisk.</div>
    <div style="background:#fff7ed;border-radius:6px;padding:0.8rem 1rem;margin:0.8rem 0;font-size:0.85rem;border-left:3px solid #f97316"><strong>&#9888; Concerns:</strong> The current high coverage in Tier-1 outlets suggests that the market has probably priced in the risks, and any positive headlines could lead to a swift reversal in sentiment.</div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Private Narrative Log</div><div style="margin-bottom:1rem;padding:0.8rem 1rem;background:white;border-radius:6px;border-left:3px solid #d1d5db;box-shadow:0 1px 2px rgba(0,0,0,0.04)"><div style="font-size:0.85rem;color:#374151;line-height:1.6">In this first review, I've observed that the narrative around Novo Nordisk has developed quickly into mainstream coverage, indicating a saturation point without fresh catalysts on the horizon. Given the risk of a sudden positive sentiment shift and the lack of new insights, I believe it's prudent to abandon the position for now. I'll remain alert for relevant updates that could reignite the short case in the future.</div><div style="font-size:0.7rem;color:#9ca3af;margin-top:4px">Cycle 1 &middot; 2026-02-19T17:09</div></div></div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Due Diligence Log</div><div style="margin-bottom:0.8rem;padding:0.6rem 1rem;background:#f9fafb;border-radius:6px;border-left:3px solid #16a34a"><div style="display:flex;justify-content:space-between;align-items:center;margin-bottom:4px"><span style="font-weight:700;color:#16a34a">TRADE</span><span style="font-size:0.7rem;color:#9ca3af">pre_trade &middot; </span></div><div style="font-size:0.82rem;color:#374151">Fresh signal (3h), price stable (0.0% move), confidence 44%</div><div style="font-size:0.72rem;color:#6b7280;margin-top:3px">Price: $49.23 | Move: 0.0% | Staleness: 3h</div></div><div style="margin-bottom:0.8rem;padding:0.6rem 1rem;background:#f9fafb;border-radius:6px;border-left:3px solid #16a34a"><div style="display:flex;justify-content:space-between;align-items:center;margin-bottom:4px"><span style="font-weight:700;color:#16a34a">TRADE</span><span style="font-size:0.7rem;color:#9ca3af">watch_check &middot; </span></div><div style="font-size:0.82rem;color:#374151">Fresh signal (3h), price stable (0.0% move), confidence 44%</div><div style="font-size:0.72rem;color:#6b7280;margin-top:3px">Price: $49.23 | Move: 0.0% | Staleness: 3h</div></div></div>
    <div style="margin:1.5rem 0"><div style="font-size:0.8rem;color:#6b7280;font-weight:700;text-transform:uppercase;letter-spacing:0.05em;margin-bottom:0.8rem;padding-bottom:4px;border-bottom:1px solid #e5e7eb">Price History</div><div style="display:flex;flex-wrap:wrap;gap:6px"><span style="font-size:0.7rem;color:#9ca3af;padding:2px 6px;background:#f9fafb;border-radius:4px">14:21 $49.23 </span><span style="font-size:0.7rem;color:#9ca3af;padding:2px 6px;background:#f9fafb;border-radius:4px">15:21 $49.23 </span><span style="font-size:0.7rem;color:#9ca3af;padding:2px 6px;background:#f9fafb;border-radius:4px">16:21 $49.23 </span><span style="font-size:0.7rem;color:#7c3aed;padding:2px 6px;background:#f9fafb;border-radius:4px">17:22 $49.23 </span><span style="font-size:0.7rem;color:#7c3aed;padding:2px 6px;background:#f9fafb;border-radius:4px">18:22 $49.23 </span><span style="font-size:0.7rem;color:#7c3aed;padding:2px 6px;background:#f9fafb;border-radius:4px">19:23 $49.23 </span><span style="font-size:0.7rem;color:#7c3aed;padding:2px 6px;background:#f9fafb;border-radius:4px">20:23 $49.23 </span></div></div>

    <div style="margin-top:2rem;padding-top:1rem;border-top:1px solid #e5e7eb;font-size:0.72rem;color:#9ca3af;text-align:center">
        Position #233 &middot; Updated 2026-02-19 20:54 UTC &middot; <a href="../" style="color:#9ca3af">Back to Trading Sheet</a>
    </div>
</div>
</body>
</html>